Vistagen Therapeutics, Inc. Common Stock (VTGN)
Vistagen Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel psychological and neurological treatments. It specializes in innovative medicines for mental health and neurological disorders, leveraging its proprietary research platform to address unmet medical needs.
Company News
VistaGen Therapeutics (VTGN) has received a rating upgrade to a Zacks Rank #2 (Buy), reflecting an upward trend in earnings estimates, which is a powerful force impacting stock prices. The upgrade positions the company in the top 20% of Zacks-covered stocks in terms of estimate revisions, suggesting the stock might move higher in the near term.
The mean of analysts' price targets for VistaGen Therapeutics, Inc. (VTGN) points to a 160% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Are you looking for penny stocks to buy? Are you grappling with… The post VistaGen Therapeutics (VTGN Stock) Exploded 3,471% Here’s Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Â VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a company developing therapeutics to transform the treatment paradigm for patients suffering from anxiety, depression and other central nervous system (CNS) disorders, today reported results for its third fiscal quarter ended December 31...